ASH 2022 | Beat AML Master sub-study: enasidenib and response-driven addition of azacitidine in IDH2m AML
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares some results from a sub-study of the Beat-AML Master trial (NCT03013998), which is evaluating the safety and efficacy of enasidenib followed by response-driven addition of azacitidine for the treatment of patients with IDH2-mutated acute myeloid leukemia (AML). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PTC Therapeutics and Syros: Membership on an entity’s Board of Directors or advisory committees; Syndax: Consultancy, Research Funding; Amgen, AbbVie, Seattle Genetics, and Biotheryx: Consultancy; Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Auron Therapeutics: Current equity holder in private company; PinotBio, Bristol Myers Squibb, Jazz Pharmaceuticals, Foghorn Therapeutics, Blueprint Medicines, Gilead Sciences, Janssen Pharmaceuticals: Consultancy; Bayer: Research Funding.
